Jiangsu Kanion Pharmaceutical Co. Ltd.SSE: 600557

(600557)"Jiangsu Kanion Pharmaceutical Co., Ltd."Report for Q3 2026

Oct 30, 2026 · Issued by Jiangsu Kanion Pharmaceutical Co. Ltd. via Shanghai Stock Exchange

Filed with SSE · Stock code 600557 · Oct 30, 2026

On 6ix: 6ix.com/news/600557jiangsu-kanion-pharmaceutical-co-ltdreport-for-q3-2026

Report for Q3 2026

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

6ix is reading this filing.

View original source (Shanghai Stock Exchange)Jiangsu Kanion Pharmaceutical Co. Ltd. on 6ix

Earlier from Jiangsu Kanion Pharmaceutical

(600557)"Jiangsu Kanion Pharmaceutical Co., Ltd."Announcement on Receipt of the Clinical Trial Approval Notice for Shiwei Anchang GranulesOct 23
(600557)"Jiangsu Kanion Pharmaceutical Co., Ltd."Announcement on Departure of Senior ExecutiveOct 17
(600557)"Jiangsu Kanion Pharmaceutical Co., Ltd."Announcement on Progress in Repurchasing Shares through Call AuctionOct 10
Semi-annual Report for 2026Aug 28
Announcement on Receipt of the Clinical Trial Approval Notice for Qihuang Zhengqi GranulesJul 22

All Jiangsu Kanion Pharmaceutical news releases

Follow Jiangsu Kanion Pharmaceutical into a list and get an email when it puts out news.

Follow Jiangsu Kanion Pharmaceutical